A1394
4-Aminophenyl α-D-mannopyranoside
≥98% (TLC)
Synonym(s):
p-aminophenyl alpha-D-mannoside
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C12H17NO6
CAS Number:
Molecular Weight:
271.27
MDL number:
UNSPSC Code:
12352201
PubChem Substance ID:
NACRES:
NA.25
Quality Level
Assay
≥98% (TLC)
form
powder
optical activity
[α]/D 123.00 to 135.00°, c = 9.00-11.00 mg/mL in methanol
technique(s)
thin layer chromatography (TLC): suitable
color
white to yellow cast
solubility
H2O: soluble
storage temp.
2-8°C
SMILES string
Nc1ccc(OC2OC(CO)C(O)C(O)C2O)cc1
InChI
1S/C12H17NO6/c13-6-1-3-7(4-2-6)18-12-11(17)10(16)9(15)8(5-14)19-12/h1-4,8-12,14-17H,5,13H2
InChI key
MIAKOEWBCMPCQR-UHFFFAOYSA-N
Application
4-Aminophenyl α-D-mannopyranoside is used to modify the surface of liposomes to increase uptake kinetics.
Other Notes
To gain a comprehensive understanding of our extensive range of Monosaccharides for your research, we encourage you to visit our Carbohydrates Category page.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Regulatory Information
涉药品监管产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
P K Das et al.
Experientia, 38(5), 629-630 (1982-05-15)
Antiserum was raised against an aminophenyl derivative of D-mannose grafted on to a liposomal surface. As characterized by immunodiffusion, quantitative precipitation and hapten inhibition, the antiserum was found to contain mannose specific antibodies in addition to antibodies against the aromatic
Xue Ying et al.
Journal of controlled release : official journal of the Controlled Release Society, 141(2), 183-192 (2009-10-06)
Chemotherapy for brain glioma has been of limited value due to the inability of transport of drug across the blood-brain barrier (BBB) and poor penetration of drug into the tumor. For overcoming these hurdles, the dual-targeting daunorubicin liposomes were developed
M Triggiani et al.
Journal of immunology (Baltimore, Md. : 1950), 164(9), 4908-4915 (2000-04-26)
Secretory phospholipases A2 (sPLA2s) are a group of extracellular enzymes that release fatty acids at the sn-2 position of phospholipids. Group IIA sPLA2 has been detected in inflammatory fluids, and its plasma level is increased in inflammatory diseases. To investigate
Sumio Chono et al.
Drug development and industrial pharmacy, 36(1), 102-107 (2009-08-07)
The effect of surface-mannose modification on aerosolized liposomal delivery to alveolar macrophages (AMs) was evaluated in vitro and in vivo. 4-Aminophenyl-α-D-mannopyranoside (Man) was used for surface-mannose modification, and mannosylated liposomes with various mannosylation rates (particle size: 1000 nm) were prepared.
Xue Ying et al.
Pharmacology, 87(1-2), 105-114 (2011-02-02)
To circumvent the problem of transporting anticancer drugs across the blood-brain barrier (BBB) to target brain tumors, we have previously developed dual-targeting daunorubicin liposomes modified with 4-aminophenyl-α-D-manno-pyranoside and transferrin molecules. The objective of the present study was to evaluate the
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service